PMID: 6108517Oct 1, 1980Paper

The contribution of alpha 1-acid glycoprotein, lipoproteins, and albumin to the plasma binding of perazine, amitriptyline, and nortriptyline in healthy man

Naunyn-Schmiedeberg's Archives of Pharmacology
M Brinkschulte, U Breyer-Pfaff

Abstract

Parameters for the binding of perazine (PER), amitriptyline (AT) and nortriptyline (NT) to plasma and to single plasma proteins were determined by equilibrium dialysis. The highest affinity (K at least 10(5) M-1) and lowest capacity (first site 1 mol/mol) towards all three drugs was exhibited by alpha 1-acid glycoprotein (alpha 1-AGP). From the parameters, alpha 1-AGP was estimated to contribute 43% to total binding of PER and 49 and 31%, respectively, to AT and NT binding in samples with normal protein concentrations. Fractions bound to total lipoproteins would amount to 32% (PER), 40 (AT) and 52% (NT), respectively, while the contribution of albumin would range from 11% (AT) to 25% (PER). The extent of the binding to plasma was compared with that to single proteins and their mixtures. Binding to combinations of alpha 1-AGP, lipoproteins and albumin exceeded that to plasma with PER but not with AT and NT. This leads to the assumption that additional plasma constituents interfere with PER binding.

References

Jul 31, 1979·Naunyn-Schmiedeberg's Archives of Pharmacology·M Brinkschulte, U Breyer-Pfaff
Apr 1, 1977·Journal of Pharmaceutical Sciences·J J Vallner
Mar 1, 1979·Clinical Pharmacology and Therapeutics·A Danon, Z Chen
Feb 5, 1976·The New England Journal of Medicine·J Koch-Weser, E M Sellers
Jan 1, 1971·Clinica Chimica Acta; International Journal of Clinical Chemistry·B T DoumasH G Biggs
May 1, 1980·Pharmakopsychiatrie, Neuro-Psychopharmakologie·J SchleyB Müller-Oerlinghausen
Nov 1, 1980·European Journal of Clinical Pharmacology·J SchleyB Müller-Oerlinghausen

❮ Previous
Next ❯

Citations

Sep 1, 1984·Naunyn-Schmiedeberg's Archives of Pharmacology·G Nyberg, E Mårtensson
Mar 1, 1983·Naunyn-Schmiedeberg's Archives of Pharmacology·W E Müller, A E Stillbauer
Jan 1, 1982·European Journal of Clinical Pharmacology·M BrinkschulteU Breyer-Pfaff
Jan 1, 1985·European Journal of Clinical Pharmacology·C B Kristensen
Apr 1, 1995·European Journal of Drug Metabolism and Pharmacokinetics·I TorresR Calvo
Jun 8, 2007·Analytical and Bioanalytical Chemistry·Ulf Mathias, Manfred Jung
Jan 1, 1992·The Journal of Pharmacy and Pharmacology·T MiyoshiM Otagiri
Aug 10, 2001·Drug Metabolism Reviews·Z H Israili, P G Dayton
Apr 21, 1998·Journal of Pharmaceutical Sciences·K M Wasan, S M Cassidy
Dec 1, 1991·Biopharmaceutics & Drug Disposition·W G ShinN D Kim
Dec 3, 2015·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Cong BiDavid S Hage
Jun 11, 2011·Journal of Separation Science·Michelle J Yoo, David S Hage
Sep 1, 1983·British Journal of Clinical Pharmacology·E PikeP K Lunde
Jan 1, 1984·The Journal of Pharmacy and Pharmacology·M R ShamiB Whiting
Mar 1, 1982·The Journal of Pharmacy and Pharmacology·S El-GamelW E Müller
Nov 1, 1988·The Journal of Pharmacy and Pharmacology·C B EapP Baumann
Jan 1, 1990·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·M Furlanut, P Benetello
Jan 25, 2005·Therapeutic Drug Monitoring·Peter H Hinderling, Dieter Hartmann
Feb 1, 1993·Pain·R FainsingerE Bruera
Feb 1, 1982·Acta Pharmacologica Et Toxicologica·C B Kristensen, L F Gram
Aug 1, 1982·Acta Pharmacologica Et Toxicologica·R VirtanenK Irjala
May 1, 1982·Biochemical Pharmacology·M Brinkschulte, U Breyer-Pfaff

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.